on NEOVACS (EPA:ALNEV)
Neovacs: 2024 Annual Results and Outlook
On May 6, 2025, Neovacs, a biopharmaceutical company listed on Euronext Growth, reported its 2024 annual results. The company has made significant progress in developing an mRNA vaccine to treat allergies, with studies in non-human primates showing promising efficacy without adverse effects. This project is valued at €56-98 million, with a potential of €402 million if clinical trials are successful.
Neovacs is also continuing its investments, although the value of its portfolio has decreased from €23.3 million to €19.1 million. Regarding Pharnext, future developments could positively impact Neovacs' assets if the drug PXT3003 obtains market authorization in China.
Despite financial challenges, the company improved its sequential financial results, reducing its annual net losses to €32.9 million from €8.7 million in 2023. A new financing line is being sought to cover the estimated needs of €9.5 million in 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news